Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia a randomized clinical trial

JAMA Psychiatry

Volumn 72, Issue 8, 2015, Pages 822-829

  Subotnik, Kenneth L ^a   Casaus, Laurie R ^a   Ventura, Joseph ^a   Luo, John S ^a   Hellemann, Gerhard S ^a   Gretchen Doorly, Denise ^a   Marder, Stephen ^a,b   Nuechterlein, Keith H ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HEMOGLOBIN A1C; PROLACTIN; RISPERIDONE; DELAYED RELEASE FORMULATION; NEUROLEPTIC AGENT;

ADULT; AKATHISIA; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMPARATIVE EFFECTIVENESS; DELUSION; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DRUG FORMULATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HALLUCINATION; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; INVOLUNTARY MOVEMENT; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PROLACTIN BLOOD LEVEL; PSYCHOLOGICAL WELL BEING; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RISK REDUCTION; SCHIZOPHRENIA; SYSTOLIC BLOOD PRESSURE; COGNITIVE THERAPY; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; EARLY INTERVENTION; HEALTH BEHAVIOR; MULTIMODALITY CANCER THERAPY; ORAL DRUG ADMINISTRATION; PROCEDURES; SECONDARY PREVENTION; THERAPEUTIC USE; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DELAYED-ACTION PREPARATIONS; EARLY MEDICAL INTERVENTION; FEMALE; HEALTH BEHAVIOR; HUMANS; MALE; MEDICATION ADHERENCE; RISPERIDONE; SCHIZOPHRENIA; SECONDARY PREVENTION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84939815548     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2015.0270     Document Type: Article

References (23)

1. Subotnik KL, Nuechterlein KH, Ventura J, et al. Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Am J Psychiatry. 2011;168(3):286-292.
2. Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Clin Ther. 2008;30(12): 2378-2386.
3. Leucht C, Heres S, Kane JM, KisslingW, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia: a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res. 2011;127(1-3):83-92.
4. Lasser RA, Bossie CA, Gharabawi GM, Kane JM. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr Res. 2005;77(2-3):215-227.
5. Weiden PJ, Schooler NR,Weedon JC, Elmouchtari A, Sunakawa-McMillan A. Maintenance treatment with long-acting injectable risperidone in firstepisode schizophrenia: a randomized effectiveness study. J Clin Psychiatry. 2012;73(9):1224-1233.
6. Rosenheck RA, Krystal JH, Lew R, et al; CSP555 Research Group. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364(9):842-851.
7. MacfaddenW,MaYW, Thomas Haskins J, Bossie CA,Alphs L. Aprospective study comparing the longterm effectiveness of injectable risperidone longacting therapy and oral aripiprazole in patientswith schizophrenia. Psychiatry (Edgmont). 2010;7(11):23-31.
8. Keks NA, Ingham M, Khan A, Karcher K. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: randomised, controlled, open-label study. Br J Psychiatry. 2007;191:131-139.
9. Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010; 167(2):181-189.
10. GaebelW, Schreiner A, Bergmans P, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology. 2010;35(12):2367-2377.
11. Bai YM, Ting Chen T, Chen JY, et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry. 2007;68(8):1218-1225.
12. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: ameta-analysis of randomized trials. Schizophr Bull. 2014;40(1):192-213.
13. Malla A, Chue P, Jordan G, et al. An exploratory open-label randomized trial comparing risperidone long acting injectable (RLAI) with oral antipsychotic medication in the treatment of early psychosis. Clin Schizophr Relat Psychoses. 2013;17:1-26.
14. Nuechterlein KH, Subotnik KL, Turner LR, Ventura J, Becker DR, Drake RE. Individual placement and support for individuals with recent-onset schizophrenia: integrating supported education and supported employment. Psychiatr Rehabil J. 2008;31(4):340-349.
15. Nuechterlein KH, Dawson ME, Gitlin M, et al. Developmental processes in schizophrenic disorders: longitudinal studies of vulnerability and stress. Schizophr Bull. 1992;18(3):387-425.
16. Nuechterlein KH, Ventura J, Subotnik KL, Hayata JN, Medalia A, BellMD. Developing a cognitive training strategy for first-episode schizophrenia: integrating bottom-up and top-down approaches. Am J Psychiatr Rehabil. 2014;17(3):225-253.
17. Gretchen-Doorly D, Subotnik KL, Ventura J, Nuechterlein KH. Comparing Healthy Lifestyle Training and Cognitive Remediation in First-Episode Schizophrenia Patients: Six-Month Health Attitude and Independent Living Skills Outcomes. Ann Arbor, MI: Society for Research in Psychopathology; 2012.
18. Gretchen-Doorly D, Subotnik KL, Kite RE, Alarcon E, Nuechterlein KH. Examining the impact of a wellness-based group intervention for recent-onset schizophrenia patients: preliminary results from an ongoing trial. Paper presented at: The International Congress on Schizophrenia Research; March 20, 2009; San Diego, CA.
19. Ventura J, Lukoff D, Nuechterlein KH, Liberman RP, Green MF, Shaner A. Brief Psychiatric Rating Scale (BPRS) expanded version: scales, anchor points, and administration manual. Int JMethods Psychiatr Res. 1993;3:227-243.
20. Nuechterlein KH, Miklowitz DJ, Ventura J, Gitlin MJ, StoddardM, Lukoff D. Classifying episodes in schizophrenia and bipolar disorder: criteria for relapse and remission applied to recent-onset samples. Psychiatry Res. 2006;144(2-3):153-166.
21. Overall JE, Hollister LE, Pichot P. Major psychiatric disorders: a four-dimensional model. Arch Gen Psychiatry. 1967;16(2):146-151.
22. Bartzokis G, Lu PH, Raven EP, et al. Impact on intracorticalmyelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia. Schizophr Res. 2012;140(1-3):122-128.
23. Nuechterlein KH, Subotnik KL, Ventura J, et al. Long-acting injectable risperidone and medication adherence enhance cognition and work functioning after a first psychotic episode. Paper presented at: 14th International Congress on Schizophrenia Research; April 24, 2013; Orlando, FL.